Stockhead: Racura Oncology gains ethics approval for HARNESS-1 lung cancer trial
Stockhead: Racura Oncology gains ethics approval for HARNESS-1 lung cancer trial
Special Report: Racura Oncology has taken a significant step forward in the clinical development of its next-generation cancer therapy RC220, receiving human ethics approval for a HARNESS-1 Phase 1a/b trial in patients with EGFR-mutated non-small...
The Australian: Racura Oncology targets two new cancer markets with RC220’s unique molecular action
The Australian: Racura Oncology targets two new cancer markets with RC220’s unique molecular action
Special Report: Racura Oncology has discovered the unique molecular mechanism of action for its RC220 therapy, opening two new major potential indications to explore in a clinical setting. Read full article here....
Proactive: Turning risk into advantage: Racura Oncology’s push to make chemotherapy safer
Proactive: Turning risk into advantage: Racura Oncology’s push to make chemotherapy safer
Proactive Investors covered Racura Oncology’s cardio-oncology strategy and the potential of RC220 to make anthracycline-based chemotherapy safer for patients. The article highlights progress in our international Phase 1 trial, our dual anticancer and cardioprotective...
The Australian: ASX Health Quarterly Wrap – Progress on multiple fronts in strong start to FY26
The Australian: ASX Health Quarterly Wrap – Progress on multiple fronts in strong start to FY26
Stockhead and The Australian included Racura Oncology in an ASX healthcare company quarterly results season wrap up, which highlights ongoing progress, including new discoveries and clinical trial updates to propel growth in FY26. The...
Long Shortz with Racura Oncology: Understanding the mechanism of action that could transform cancer therapy
Long Shortz with Racura Oncology: Understanding the mechanism of action that could transform cancer therapy
Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully to discuss the groundbreaking discovery of the primary mechanism of action of their lead drug. Dr Tillett explains how understanding the drug’s mechanism increases...
News.com.au: ASX health stocks rise; Racura Oncology enjoys big week with lead drug discovery
News.com.au: ASX health stocks rise; Racura Oncology enjoys big week with lead drug discovery
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector and selects Racura Oncology as his ‘Powerplay’...
Proactive: Inside Biotech – Racura Oncology’s G4-DNA discovery sharpens clinical story
Proactive: Inside Biotech – Racura Oncology’s G4-DNA discovery sharpens clinical story
Racura Oncology has uncovered a fresh chapter in its lead cancer program, identifying a novel mechanism of action for its (E,E)-bisantrene candidate. New data shows the compound binds to G4-DNA and RNA structures —...
Long Shortz with Racura Oncology: Investor insight into Racura’s patent breakthrough
Long Shortz with Racura Oncology: Investor insight into Racura’s patent breakthrough
Racura Oncology CEO Dr Daniel Tillett spoke to Stockhead’s Tylah Tully about the company’s major scientific discovery, which has enabled a new composition of matter patent application for the (E,E)-bisantrene compound. Dr Tillett explains why...
Proactive: Racura Oncology activates Hong Kong trial site
Proactive: Racura Oncology activates Hong Kong trial site
Racura Oncology CEO Dr Daniel Tillett spoke with Proactive about the activation of the company’s first clinical site in Hong Kong for its Phase 1 RC220 trial in advanced solid tumours. Located at Queen...
Inside Racura: Introducing Dr Jose Iglesias, Chief Medical Officer at Racura Oncology
Inside Racura: Introducing Dr Jose Iglesias, Chief Medical Officer at Racura Oncology
We are pleased to share another instalment of our “Inside Racura” video interview series, introducing Chief Medical Officer Dr Jose Iglesias, who joined the Racura Oncology team in May 2025. Dr Iglesias shares what...
